Trichostatin A
Phase 2Small molecule
Trichostatin A is one of 5 small molecule programs targeting Relapsed or Refractory Hematologic Malignancies. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Relapsed or Refractory Hematologic Malignancies
#DrugCompanyPhaseTrials
1Nemtabrutinib
Merck & Co.Phase 2
BT02
BBiotroy Therapeutics
Phase 2
Trichostatin A
VVanda Pharmaceuticals
Phase 2
In Vivo CAR-T Therapy
SShanghai Zhongshan Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trichostatin A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- VVanda Pharmaceuticals